Reference desk / Entry
Ipamorelin
Also listed as: Ipamorelin acetate
Read the scope first. Then use the note and questions to examine what the evidence can answer.
- Scoped product status
- Not FDA-approved
- Evidence label
- Randomized evidence
- Status as of
Reference fields
References for these fields are listed together in Sources.
- Product and use scope
- The reviewed FDA record identifies no approved ipamorelin product.
- Route context
- The cited trial used intravenous treatment after bowel surgery.
- Mechanism
- A ghrelin-receptor agonist.
- Evidence
- A randomized postoperative-ileus trial did not show a significant efficacy advantage.
- Limitations
- That setting does not establish anti-aging or muscle-building benefit.
- Safety
- FDA flags safety uncertainties for injectable ipamorelin.
A question worth making clear
Consider how a conclusion would need to be examined if the people represented by the question changed. First describe the population attached to the reported answer, then describe the population in the proposed extension. Avoid assuming either that a difference must change the answer or that it cannot matter. Ask what reasoning or comparison would support carrying the conclusion across. By making the proposed extension explicit, readers can separate confidence in the original result from confidence in its use elsewhere and identify the evidence needed for that additional step.
- How does the population in our question differ from the population attached to the result?
- What reasoning would support carrying the conclusion from one population to the other?
- Which evidence could test the proposed extension without assuming its answer in advance?
Sources
Each date below belongs to the supplied source record. The references support the entry as a group.
- FDA safety
FDA · Checked
- FDA ipamorelin
FDA · Checked
- Beck
PubMed · Checked